News Quantified

CALC – calcimedica, inc. (US:NASDAQ)

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

4/24

08:00 am

calc

High

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica, Inc. (NASDAQ: CALC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.

CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}